PE20081477A1 - Formulacion liofilizada mab abeta - Google Patents
Formulacion liofilizada mab abetaInfo
- Publication number
- PE20081477A1 PE20081477A1 PE2007001764A PE2007001764A PE20081477A1 PE 20081477 A1 PE20081477 A1 PE 20081477A1 PE 2007001764 A PE2007001764 A PE 2007001764A PE 2007001764 A PE2007001764 A PE 2007001764A PE 20081477 A1 PE20081477 A1 PE 20081477A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- abeta
- mab
- lyophilized formulation
- histidine
- Prior art date
Links
- 239000012931 lyophilized formulation Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 abstract 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 abstract 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- -1 POLYOXYETHYLENE, OCTYL Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000001507 asparagine derivatives Chemical class 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 abstract 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 abstract 1
- 239000001590 sorbitan monolaureate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA ESTABLE, PARENTERAL DEL ANTICUERPO ABETA, EL CUAL COMPRENDE: a) ENTRE 1 Y 250mg/mL DE DICHO ANTICUERPO, b) ENTRE 0.001 Y 1% DE UN TENSIOACTIVO, TAL COMO, MONOLAUREATO DE SORBITAN, OLEIL-ETER DE POLIOXIETILENO, OCTIL FENOL-ETOXILATO, ENTRE OTROS, c) ENTRE 1 Y 100Mm DE UN TAMPON, TAL COMO L-HISTIDINA, CLORHIDRATO DE L-HISTIDINA O UNA MEZCLA DE AMBAS, d) OPCIONALMENTE ENTRE 10 Y 500Mm DE UN ESTABILIZADOR, TAL COMO HIDROXIPROPIL-ß-CICLODEXTRINA, ALBUMINA, POLIETILENGLICOL, ENTRE OTROS, Y/O 5 A 500Mm DE UN AGENTE DE TONICIDAD, COMO CLORURO DE SODIO, GLICERINA, AMINOACIDOS, ENTRE OTROS. DICHO ANTICUERPO TIENE 1-2 SITIOS DE UNION DE ANTIGENO QUE COMPRENDE ASPARAGINA GLICOSILADA EN LA REGION VARIABLE DE LA CADENA PESADA. DICHA COMPOSICION SE ENCUENTRA FORMA LIQUIDA O LIOFILIZADA, CON UN pH ENTRE 4-7 DE UTILIDAD EN EL TRATAMIENTO DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06025590 | 2006-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081477A1 true PE20081477A1 (es) | 2008-10-18 |
Family
ID=39190366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001764A PE20081477A1 (es) | 2006-12-11 | 2007-12-11 | Formulacion liofilizada mab abeta |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110070225A1 (es) |
| EP (1) | EP2094729A1 (es) |
| JP (1) | JP2010512356A (es) |
| KR (1) | KR20090104017A (es) |
| CN (1) | CN101553504A (es) |
| AR (1) | AR064220A1 (es) |
| AU (1) | AU2007331712A1 (es) |
| BR (1) | BRPI0721097A2 (es) |
| CA (1) | CA2671968A1 (es) |
| CL (1) | CL2007003583A1 (es) |
| CR (1) | CR10823A (es) |
| EC (1) | ECSP099403A (es) |
| IL (1) | IL198963A0 (es) |
| MA (1) | MA30975B1 (es) |
| MX (1) | MX2009006199A (es) |
| NO (1) | NO20092586L (es) |
| PE (1) | PE20081477A1 (es) |
| RU (1) | RU2009126420A (es) |
| TW (1) | TW200831133A (es) |
| WO (1) | WO2008071394A1 (es) |
| ZA (1) | ZA200904014B (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| JP5057967B2 (ja) | 2005-03-31 | 2012-10-24 | 中外製薬株式会社 | ｓｃ（Ｆｖ）２構造異性体 |
| KR101360671B1 (ko) | 2005-06-10 | 2014-02-07 | 추가이 세이야쿠 가부시키가이샤 | ｓｃ（Ｆｖ）２를 함유하는 의약조성물 |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| ATE517923T1 (de) * | 2005-12-12 | 2011-08-15 | Hoffmann La Roche | Antikörper gegen amyloid beta mit glykosilierung in der variablen region |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2238166B1 (en) | 2007-10-05 | 2013-11-27 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| EP2993186B1 (en) | 2008-03-14 | 2019-09-04 | Biocon Limited | A monoclonal antibody and a method thereof |
| EP2310412B1 (en) * | 2008-06-20 | 2018-02-21 | Novartis AG | Immunoglobulins with reduced aggregation |
| SG2014011365A (en) * | 2008-09-19 | 2014-05-29 | Hoffmann La Roche | Novel antibody formulation |
| AU2009314311B2 (en) | 2008-10-29 | 2013-01-10 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
| EP2362767B1 (en) | 2008-10-29 | 2017-12-06 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| AR074357A1 (es) * | 2008-11-17 | 2011-01-12 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| WO2010100179A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| CN102770157B (zh) * | 2009-11-20 | 2017-05-17 | 拜康有限公司 | 抗体的配制品 |
| KR20120110175A (ko) * | 2009-12-29 | 2012-10-09 | 에프. 호프만-라 로슈 아게 | 항체 제제 |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| RS61082B1 (sr) | 2010-02-26 | 2020-12-31 | Novo Nordisk As | Stabilno antitelo koje sadrži kompozicije |
| CA2791685C (en) | 2010-03-01 | 2019-07-23 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| EA201201227A1 (ru) | 2010-03-03 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипаратопные а-бета-связывающие полипептиды |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| WO2012028683A1 (en) * | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| SMT201700515T1 (it) | 2011-05-02 | 2018-01-11 | Millennium Pharm Inc | Formulazione per anticorpo anti- 4 7 |
| EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20140302021A1 (en) * | 2011-10-25 | 2014-10-09 | Onclave Therapeutics Limited | Antibody formulations and methods |
| MX351148B (es) * | 2012-03-08 | 2017-10-04 | Hoffmann La Roche | Formulacion de anticuerpo beta amiloide. |
| BR122019026701B1 (pt) * | 2012-03-26 | 2023-01-24 | Sanofi | Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| HK1215175A1 (zh) * | 2013-03-15 | 2016-08-19 | Bayer Healthcare Llc | 抗-催乳素受體抗體製劑 |
| EP3738613A1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| WO2016065090A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| EP3207936B1 (en) * | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN104946616A (zh) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | 一种用于体外诊断试剂的通用固体稳定剂及其使用方法 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| HUE057952T2 (hu) | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| US10125195B2 (en) * | 2015-08-19 | 2018-11-13 | Astrazeneca Ab | Stable anti-IFNAR1 formulation |
| HK1255006A1 (zh) * | 2015-09-22 | 2019-08-02 | Pfizer Inc. | 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 |
| CN114057884A (zh) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CN106620691B (zh) * | 2015-11-04 | 2020-08-21 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
| CN108472379B (zh) | 2015-12-30 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
| DK3529274T3 (da) | 2016-10-21 | 2024-06-17 | Biocon Ltd | Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus |
| CN106913869B (zh) * | 2017-03-17 | 2020-07-28 | 信达生物制药(苏州)有限公司 | 一种抗ctla-4单克隆抗体制剂及其应用 |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| AU2018321335B2 (en) * | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CN108373494A (zh) * | 2018-02-27 | 2018-08-07 | 武汉伊艾博科技有限公司 | 一种防止重组蛋白质降解的保护技术 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| WO2021136274A1 (zh) * | 2019-12-30 | 2021-07-08 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| EP4221750A4 (en) * | 2020-09-30 | 2024-11-13 | Merck Sharp & Dohme LLC | BINDING PROTEINS AND ANTIGEN-BINDING FRAGMENTS THEREOF BINDING TO ABETA |
| US20240417451A1 (en) | 2023-05-31 | 2024-12-19 | Hoffmann-La Roche Inc. | Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies |
| CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| WO2003009817A2 (en) * | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| PT2335725T (pt) * | 2003-04-04 | 2017-01-06 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| DOP2006000022A (es) * | 2005-01-28 | 2006-08-15 | Wyeth Corp | Formulaciones líquidas estabilizadas de polipetidos |
| ATE517923T1 (de) * | 2005-12-12 | 2011-08-15 | Hoffmann La Roche | Antikörper gegen amyloid beta mit glykosilierung in der variablen region |
| RU2008142359A (ru) * | 2006-03-28 | 2010-05-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Композиция человеческого моноклонального антитела к igf-1r |
-
2007
- 2007-12-11 TW TW096147285A patent/TW200831133A/zh unknown
- 2007-12-11 WO PCT/EP2007/010825 patent/WO2008071394A1/en not_active Ceased
- 2007-12-11 PE PE2007001764A patent/PE20081477A1/es not_active Application Discontinuation
- 2007-12-11 US US12/448,190 patent/US20110070225A1/en not_active Abandoned
- 2007-12-11 RU RU2009126420/10A patent/RU2009126420A/ru not_active Application Discontinuation
- 2007-12-11 BR BRPI0721097-3A patent/BRPI0721097A2/pt not_active IP Right Cessation
- 2007-12-11 MX MX2009006199A patent/MX2009006199A/es not_active Application Discontinuation
- 2007-12-11 CA CA002671968A patent/CA2671968A1/en not_active Abandoned
- 2007-12-11 CL CL200703583A patent/CL2007003583A1/es unknown
- 2007-12-11 AU AU2007331712A patent/AU2007331712A1/en not_active Abandoned
- 2007-12-11 AR ARP070105523A patent/AR064220A1/es unknown
- 2007-12-11 EP EP07856573A patent/EP2094729A1/en not_active Withdrawn
- 2007-12-11 KR KR1020097013954A patent/KR20090104017A/ko not_active Withdrawn
- 2007-12-11 CN CNA2007800455861A patent/CN101553504A/zh active Pending
- 2007-12-11 JP JP2009540650A patent/JP2010512356A/ja not_active Withdrawn
-
2009
- 2009-05-21 CR CR10823A patent/CR10823A/es not_active Application Discontinuation
- 2009-05-26 IL IL198963A patent/IL198963A0/en unknown
- 2009-06-08 MA MA31963A patent/MA30975B1/fr unknown
- 2009-06-09 ZA ZA200904014A patent/ZA200904014B/xx unknown
- 2009-06-11 EC EC2009009403A patent/ECSP099403A/es unknown
- 2009-07-07 NO NO20092586A patent/NO20092586L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200831133A (en) | 2008-08-01 |
| AU2007331712A2 (en) | 2009-07-30 |
| ECSP099403A (es) | 2009-07-31 |
| EP2094729A1 (en) | 2009-09-02 |
| KR20090104017A (ko) | 2009-10-05 |
| RU2009126420A (ru) | 2011-01-20 |
| BRPI0721097A2 (pt) | 2014-07-01 |
| NO20092586L (no) | 2009-07-17 |
| CN101553504A (zh) | 2009-10-07 |
| AR064220A1 (es) | 2009-03-18 |
| US20110070225A1 (en) | 2011-03-24 |
| JP2010512356A (ja) | 2010-04-22 |
| MX2009006199A (es) | 2009-06-22 |
| WO2008071394A1 (en) | 2008-06-19 |
| CR10823A (es) | 2009-08-12 |
| CL2007003583A1 (es) | 2008-07-18 |
| AU2007331712A1 (en) | 2008-06-19 |
| CA2671968A1 (en) | 2008-06-19 |
| ZA200904014B (en) | 2010-04-28 |
| MA30975B1 (fr) | 2009-12-01 |
| IL198963A0 (en) | 2011-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081477A1 (es) | Formulacion liofilizada mab abeta | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| PE20091328A1 (es) | Formulacion de anticuerpo | |
| PE20091327A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| CL2010000426A1 (es) | Anticuerpo humano que se une al ligando para el ox40 (ox40l o gp34) humano; metodo de produccion; y composicion farmaceutica que lo comprende (div. sol. n°2389-05). | |
| PE20120359A1 (es) | Formulacion con anticuerpo | |
| PE20070116A1 (es) | Formulacion de anticuerpos estables | |
| UA99815C2 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| CL2007003761A1 (es) | Composicion liquida de limpieza personal que comprende isetionatos de acilo graso, cosurfactante, alcanolamida y/o alquilaminaoxido, acidos grasos de cadena recta o mezcla con alcoholes grasos de cadena recta y/o aceites de hidrocarburo alifatico, la | |
| EA201200475A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| PE20140166A1 (es) | Composicion farmaceutica que comprende deferasirox | |
| CL2007001185A1 (es) | Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis | |
| PE20081610A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
| CL2004000731A1 (es) | Formulacion liquida que comprende una proteina o anticuerpo en cantidad de 100 a 260 mg/ml, arginina-hcl en cantidad de 50 a 200 mm, histidina en cantidad de 10 a 100 mm, polisorbato en cantidad de 0,01% a 0,1%, ph entre 5,5 a 7,0, viscosidad cinetic | |
| BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
| AR052545A1 (es) | Suspension no acuosa inyectable | |
| CY1114904T1 (el) | Prlr-ειδικο αντισωμα και χρησεις αυτου | |
| AR091961A1 (es) | Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b) | |
| PE20171512A1 (es) | Anticuerpos anti-fap | |
| AR060165A1 (es) | Proteina de suero como vehiculo de entrega para un agente activo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |